PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2640
https://www.valueinhealthjournal.com/article/S1098-3015(19)35018-1/fulltext
Title :
PSY12 COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS SECUKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS BASED ON THE ECLIPSE TRIAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)35018-1&doi=10.1016/j.jval.2019.09.2640
First page :
Section Title :
Open access? :
No
Section Order :
12319